We are considering joining a clinical trial for Revlimid (10mg) + vorinostat (200 to 400mg) as a maintenance therapy for a high risk patient, who has had a complete response after vrd induction therapy and asct.
Trial is focused on dosage tolerance for vorinostat.
Any views on efficacy or side effects? Thanks
Forums
3 posts
• Page 1 of 1
Re: Revlimid + Vorinostat for maintenance // clinical trial
Hello,
It is impossible to predict the efficacy and that is exactly why the study is being done. In general vorinostat is well tolerated and convenient (oral). You could learn more about vorinostat (Zolinza) by looking at the website for this drug(www.zolinza.com). The drug is approved by the FDA for the treatment of cutaneous T-cell lymphoma only at this time. This type of therapy (epigenetic) holds great promise in the treatment of cancer in general. In general I strongly encourage all of my patients to participate in clinical trials because we need to advance the field of myeloma treatment as quickly as possible. This can only be done with research. We must not and cannot accept the status quo.
It is impossible to predict the efficacy and that is exactly why the study is being done. In general vorinostat is well tolerated and convenient (oral). You could learn more about vorinostat (Zolinza) by looking at the website for this drug(www.zolinza.com). The drug is approved by the FDA for the treatment of cutaneous T-cell lymphoma only at this time. This type of therapy (epigenetic) holds great promise in the treatment of cancer in general. In general I strongly encourage all of my patients to participate in clinical trials because we need to advance the field of myeloma treatment as quickly as possible. This can only be done with research. We must not and cannot accept the status quo.
-
Dr. Edward Libby - Name: Edward Libby, M.D.
Beacon Medical Advisor
Re: Revlimid + Vorinostat for maintenance // clinical trial
Thank you for your response. I agree that clinical trials are important to developing effective treatments.
The patient has a DVT and is on Warfarin to manage. Merck reports that a potential side effect of Vorinostat is DVT and pulmonary embolism, so we are being extra thorough in considering next steps - particularly when the phase 1 trial is focused principally on maximum tolerated dose.
All input welcome.
The patient has a DVT and is on Warfarin to manage. Merck reports that a potential side effect of Vorinostat is DVT and pulmonary embolism, so we are being extra thorough in considering next steps - particularly when the phase 1 trial is focused principally on maximum tolerated dose.
All input welcome.
3 posts
• Page 1 of 1
Return to Treatments & Side Effects